Lupin launches first U.S. long-acting injectable from Nanomi—what does it mean for its specialty drug future?

What does Lupin’s FDA approval for risperidone LAI mean for its U.S. injectable strategy?

Lupin Limited (NSE: LUPIN, BSE: 500257) has received final approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for risperidone extended-release injectable suspension in three dosage strengths—25 mg, 37.5 mg, and 50 mg per vial. The Mumbai-based pharmaceutical major secured 180-day Competitive Generic Therapy (CGT) exclusivity with the launch, signaling a major step forward for its U.S. generics and complex injectables strategy.

The approved formulation is the first product to emerge from Nanomi B.V., Lupin’s Netherlands-based subsidiary focused on long-acting injectables (LAIs). The risperidone LAI leverages Nanomi’s proprietary microsphere technology designed for sustained drug release over weeks to months. This milestone positions Lupin at the leading edge of a high-growth segment in the U.S. market, which is seeing rising demand for once-monthly or less frequent psychiatric drug delivery formats.

Analysts tracking Indian pharmaceutical firms noted that first-cycle FDA approvals, especially those involving complex injectables, are viewed as high-value indicators of scientific execution and regulatory credibility. The 180-day CGT exclusivity will allow Lupin to tap early-mover pricing power in a product category that generated an estimated USD 190 million in annual sales in the U.S. as of July 2025, according to IQVIA data.

How does Nanomi’s microsphere platform support sustained-release injectables and lifecycle innovation?

Nanomi’s technology—at the core of Lupin’s newly approved product—uses uniform biodegradable microspheres that enable precise and prolonged drug delivery. The particle engineering ensures consistent plasma levels and reduces the frequency of injections. According to Lupin’s internal documentation, this also translates to improved patient adherence and reduced clinic visits for chronic neuropsychiatric conditions.

This injectable platform is not merely a delivery upgrade—it opens up lifecycle management opportunities. By using Nanomi’s long-acting formulations, Lupin can extend the commercial viability of in-market drugs approaching patent cliffs or offer alternative delivery pathways for pipeline candidates. Executive leadership emphasized that the risperidone LAI approval validates the company’s broader platform ambitions in high-barrier specialty products.

CEO Vinita Gupta called the approval “a testament to the capabilities we have established for complex injectables,” underlining the company’s plan to evolve its U.S. pipeline toward higher-margin, differentiated formulations. Dr. Shahin Fesharaki, Chief Scientific Officer, added that this was a “critical milestone” for cross-functional development teams and a forward leap in expanding the company’s long-acting injectable portfolio.

Why does CGT exclusivity matter in the competitive U.S. generics and injectables market?

CGT designation, and the corresponding 180-day exclusivity window, allows generic drugmakers to launch without immediate competition from other generics, enhancing pricing and volume capture potential. The FDA awards this status to ANDAs for drugs with limited competition and unmet patient need—criteria that Lupin’s risperidone injectable appears to meet, particularly as a generic equivalent of Janssen’s Risperdal Consta®.

During this protected launch period, Lupin can capitalize on pricing premium before broader market erosion typically seen in generics. In the past, CGT launches have been associated with significant EBITDA margin boosts for Indian pharma exporters, especially those operating in high-cost injectable categories. This makes the risperidone LAI a likely contributor to Lupin’s near-term U.S. revenue momentum and margin expansion in FY26.

Institutional investors have closely monitored Lupin’s pipeline transition, and this approval strengthens the firm’s argument that it can move beyond oral solids and lower-margin generics to become a more defensible player in the U.S. healthcare system.

How does risperidone LAI fit into Lupin’s central nervous system (CNS) and specialty drug ambitions?

Risperidone long-acting injectable is indicated for the treatment of schizophrenia and for maintenance treatment of bipolar I disorder—two core areas within the CNS therapy vertical. Lupin already has a presence in this segment through oral generics and APIs, but the approval signals a vertical move into complex delivery systems with higher regulatory and manufacturing barriers.

The broader strategy, as articulated in multiple investor briefings, is to develop a self-reinforcing specialty portfolio anchored in injectables, inhalation products, and biosimilars. With this milestone, Lupin gains not only a valuable U.S. launch asset but also an operational proof point that enhances the credibility of future pipeline candidates from the Nanomi platform.

Gupta reaffirmed this during the announcement, stating that Lupin will “leverage the Nanomi platform for novel long-acting injectables that meet unmet patient needs.” Analysts interpreted this as an indication that the company could extend its platform to oncology, pain, or metabolic disorders, where patient-friendly delivery formats are in high demand.

How does this align with Lupin’s global operations and manufacturing footprint?

Lupin’s injectable strategy is supported by its global manufacturing network, including facilities in India and the U.S., along with Nanomi’s R&D base in the Netherlands. The company operates 15 manufacturing sites and seven R&D centers worldwide. Its Naples, Florida headquarters oversees the U.S. commercial operations, which account for a significant portion of revenue.

With the U.S. market facing rising drug shortages, especially in hospital-administered formulations, manufacturers like Lupin are being viewed more favorably by health systems and payers that are rethinking supply chain dependencies. Nanomi’s European base also gives Lupin a foothold in the region’s regulatory landscape for future LAI filings beyond the U.S., especially in markets like Germany and the UK.

According to sector observers, the convergence of CGT exclusivity, platform validation, and vertical integration positions Lupin as one of the few Indian pharma players to offer end-to-end injectable innovation from concept to clinic.

What does the future pipeline look like for Nanomi and Lupin’s LAI segment?

While Lupin has not disclosed the full pipeline details of upcoming Nanomi-based products, executives have repeatedly signaled their intention to scale the platform. In previous earnings calls, Lupin’s management referenced R&D efforts underway in areas including psychiatry, endocrinology, and women’s health.

Given the commercial success of LAI formats in the U.S.—with blockbuster examples like Invega Sustenna and Vivitrol—investors will likely expect additional filings in the next 12–24 months. Future launches in differentiated categories could further de-risk Lupin’s U.S. exposure and align with its shift away from legacy generics, where price erosion continues to pressure margins.

R&D spending has remained elevated for Lupin, with around 8–9% of annual revenue allocated toward innovation. The firm’s internal targets for its specialty and complex generics division also suggest an ambition to cross the USD 1 billion mark in U.S. sales contribution from differentiated formats by the end of FY27.

Why Lupin’s risperidone LAI approval is more than a product—it’s a platform inflection

Lupin’s U.S. FDA approval for risperidone extended-release injectable may appear, on the surface, to be a generic launch milestone—but it is more appropriately viewed as a platform inflection point. With 180-day CGT exclusivity in hand, the Indian pharma firm not only secures early revenues but also establishes a clinical and regulatory precedent for the Nanomi long-acting injectable technology. The move aligns with broader institutional interest in specialty drugs, high-barrier injectables, and lifecycle extension strategies. As the American pharma landscape shifts toward patient-centric delivery formats, Lupin appears well-positioned to compete on both scientific and commercial grounds.